Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
Rebekah PenningtonAbualbishr AlshreefLaura FlightAndrew MetryEdith PokuPhilip HykinSobha SivaprasadAndrew Toby PrevostJoana C VasconcelosCaroline MurphyJoanna KellyYit YangAndrew John LoteryMichael WilliamsJohn BrazierPublished in: PharmacoEconomics (2021)
Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior to the licensed agents.